There are five major PGs (prostaglandins/prostanoids) produced from arachidonic acid via the COX (cyclo-oxygenase) pathway: PGE 2 , PGI 2 (prostacyclin), PGD 2 , PGF 2α and TXA 2 (thromboxane A 2 ). They exert many biological effects through specific G-protein-coupled membrane receptors, namely EP (PGE 2 receptor), IP (PGI 2 receptor), DP (PGD 2 receptor), FP (PGF 2α receptor) and TP (TXA 2 receptor) respectively. PGs are implicated in physiological and pathological processes in all major organ systems, including cardiovascular function, gastrointestinal responses, reproductive processes, renal effects etc. This review highlights recent insights into the role of each prostanoid in regulating various aspects of renal function, including haemodynamics, renin secretion, growth responses, tubular transport processes and cell fate. A thorough review of the literature since Y2K (year 2000) is provided, with a general overview of PGs and their synthesis enzymes, and then specific considerations of each PG/prostanoid receptor system in the kidney.
developmental biology, with specific consideration of angiogenesis and cell motility (gastrulation and cancer metastasis) in the zebrafish. PG production involves three steps: (i) the release of arachidonic acid from membrane phospholipids by PLA 2 (phospholipase A 2 ); (ii) catalysis by COXs (COX-1, COX-2 and COX-3) to an intermediate endoperoxide (PGH 2 ); and (iii) conversion into PGs by specific synthases/isomerases. NSAIDs (non-steroidal anti-inflammatory drugs) inhibit COX activity and prevent PG production. There are several extensive reviews that cover PG synthesis and biology written since the 1990s [2] [3] [4] [5] [6] [7] [8] [9] [10] .
With the start of the new millennium/Y2K (year 2000), many advances have been made to further our understanding of these PG-synthesizing enzymes and the synthesis of a given prostanoid. In particular, most studies since Y2K have emphasized the complexity of PG synthesis, implicating cross-talk or coupling between all three groups of enzymes (phospholipases, COXs and terminal synthases) rather than the focus in the 1990s on COXs. For instance, much work has been accomplished to clarify our understanding of arachidonic acid release from the membrane and the involvement of specific phospholipases. Briefly, arachidonic acid is released from membrane phospholipids primarily by the action of PLA 2 , and serves as a precursor for eicosanoid signalling molecules, including leukotrienes, hydroxyeicosatetraenoic acids and PGs. Activation of phospholipases is highly dependent on hormonal stimulation, and many recent studies have helped clarify this process. Although new types of PLA 2 (secretory, intracellular and cytosolic) are continually being identified (reviewed by Murakami and Kudo [11] ), the key cPLA 2 (cytosolic PLA 2 ) is type IV cPLA 2 , and this enzyme appears to play a primary role in determining arachidonic acid release, especially in the kidney. For instance, Cui et al. [12] have recently reported a critical role for cPLA 2 in H 2 O 2 -mediated arachidonic acid release from primary proximal tubule cells, as well as the activation of various kinases [p38 MAPK (mitogen-activated protein kinase), ERK (extracellularsignal-regulated kinase) 1/2 and Akt1]. In another study, by Han et al. [13] , H 2 O 2 -stimulated arachidonic acid release was examined in murine mesangial cell lines lacking sPLA 2 (secretory PLA 2 ) or cPLA 2 to determine their individual contribution. Once again, cPLA 2 was needed for arachidonic acid release, but sPLA 2 played a regulatory role in that their activation enhanced cPLA 2 -mediated release of arachidonic acid. Likewise, Mounier et al. [14] have demonstrated the same dependence on cPLA 2 for the release of arachidonic acid, whereas sPLA 2 promotes IL (interleukin)-1β-stimulated arachidonic acid release. There is also the possibility of cross-talk with other types of phospholipases; for instance, PLD 2 (phospholipase D 2 ) can regulate PLA 2 and, conversely, PLA 2 can facilitate the activation of PLD 2 [15] , which renders the system quite complex.
In addition to cross-talk between various phospholipases, the regulation of arachidonic acid release is complicated by the functional interaction between phospholipases and COXs. In a study by Murakami and co-workers [16] , distinct PLA 2 (cytosolic type IV, and secretory types IIA and V) and COX enzymes were expressed in HEK-293 cells (human embryonic kidney cells) to study their functional coupling and its relevance to immediate (bradykinin-stimulated) or delayed (IL-1-stimulated) PGE 2 synthesis. This study revealed that when COX (COX-1 + COX-2) was expressed without PLA 2 , COX-1 is favoured in the presence of high exogenous arachidonic acid, whereas COX-2 is favoured when levels are low. When COX is transfected with PLA 2 (all three types), COX-2 is important for delayed PG synthesis responses, but both COX isoforms are involved in the immediate response, and extracellular secretory phospholipases were important for paracrine regulation of PG synthesis in co-culture systems. Accordingly, Takano et al. [17] have shown that there is no preferential coupling of cPLA 2 to either COX isoform, but that arachidonic acid released by sPLA 2 in the absence of cPLA 2 is not metabolized by COX. In another study using chimaeric cPLA 2 that translocates to the plasma membrane rather than the perinuclear milieu upon cell stimulation, Murakami et al. [18] have shown that perinuclear localization of cPLA 2 is necessary for coupling with COX.
COXs oxidize arachidonic acid to form PGG 2 and then reduce PGG 2 to form PGH 2 , the intermediate endoperoxide that is a substrate for terminal synthases. Although COX-1 is constitutively expressed in most tissues, COX-2 is the inducible form. Thus up until the start of the new millennium, it was widely believed that prostanoids (PGs) derived from COX-1 play a homoeostatic role, whereas those from COX-2 would be harmful and, thus, could be therapeutically targeted in various diseases. However, the advent of specific COX-2 inhibitors in the mid-to-late 1990s has led to substantial progress in the area of COX/PG physiology, demonstrating that this oversimplification of protective compared with harmful COX is misleading. A detailed description of the individual COX isoforms and their renal function is beyond the scope of this review, but many recent reviews have addressed this topic [8, [19] [20] [21] [22] [23] . Although the focus on selective COX inhibition and its usefulness in preventing unwarranted adverse effects of NSAIDs continues, as we approached the middle of the first decade of the millennium, prompted by the cardiovascular complications associated with COX-2-selective NSAIDs in shifting the balance between PGI 2 and TXA 2 [24] [25] [26] , we observed a shift in the focus on COX-2 inhibitors as the miracle drugs alleviating NSAID toxicity into studies taking a closer look at the contribution of each COX isoform to distinct pools of prostanoids and their involvement in specific biological processes. For example, recent work by Stichtenoth et al. [27] has clearly demonstrated that in healthy volunteers COX-2 plays a key role in renin release from the macula densa, and COX-1 is important for systemic and renal PGE 2 synthesis, but renal PGI 2 synthesis is COX-2-dependent. This information was important in highlighting the potential harm in using COX-2-selective NSAIDs for renal function.
It is now widely recognized that both COX-1 and COX-2 are implicated in renal health and disease, with differing cellular and subcellular expression profiles throughout the kidney and variable and preferential coupling to terminal synthases which determines the pool of PGs being synthesized. In a recent study by Qi et al. [28] , this differential contribution of each COX to a specific pool of prostanoids was examined in COX-1-and COX-2-inhibited mouse kidneys using GC/MS. COX-1 inhibition reduced cortical and medullary PGs, whereas COX-2 inhibition only reduced medullary prostanoids. However, they also report that Ang (angiotensin) II infusion increased COX-2-derived vasodilatory PGE 2 and PGI 2 . In another study, Hetu and Riendeau [29] examined the contribution of constitutive COX-2 to renal prostanoid biosynthesis using LC/MS. They showed that selective COX-2 inhibition decreased total renal prostanoids by 35-50 %, including 6-oxo-PGF 1α , PGE 2 , PGD 2 and TXB 2 (a TXA 2 metabolite). Furthermore, Warford-Woolgar et al. [30] compared COX levels in diseased (Han/Sprague Dawley-cy rat) and healthy kidneys, showing that COX-1 is higher in the diseased kidney, but COX-2 levels were lower than healthy kidneys. Although the ratio of COX-1/COX-2 was higher in diseased kidneys, the predominant activity was due to COX-2 in both cases. Furthermore, the PG profile was determined and TXB 2 > 6-keto-PGF 1α > PGE 2 in diseased kidneys. Further support for the contribution of COX-2 to renal PG synthesis is provided by Lomnicka et al. [31] , showing the effect of non-selective NSAIDs (aspirin) compared with COX-2-specific inhibition (celecoxib). Not only was COX-2 inhibition more effective in suppressing prostanoid biosynthesis in normal rabbit kidneys, but it also lowered the ratio of PGI 2 /TXA 2 in the medulla. Things become quite complicated by the fact that there is also crosstalk with other eicosanoid-forming enzymes, such as lipoxygenases. Recently, this interaction has been shown to potentially influence the course of diabetic kidney disease. For instance, Xu et al. [32] have shown that 12/15-lipoxygenase and COX-2 pathways can activate each other in rat mesangial cells treated with high glucose, in db/db and streptozotocin-diabetic mice (models of Type 2 and Type 1 diabetes mellitus respectively). This cross-talk influences the severity of the disease. The consensus arising from all of these studies is that nonselective and selective NSAIDs alike may be an inappropriate means of treating inflammatory and other conditions, rather more specifically targeting terminal synthases or individual PG receptor pathways should be the focus for future therapeutic strategies, especially in avoiding renal side effects.
Another enticing premise that has emerged since Y2K is the identification of a third COX isoform, COX-3, and its potential as a target for acetaminophen. COX-3 is a spliced variant of the COX-1 gene isolated from canine brain that retains intron 1. Unlike COX-1 and COX-2, this isoenzyme was highly responsive to acetaminophen [33] . It was also detected in human cerebral cortex and heart; however, insertion of intron 1 caused a frameshift possibly resulting in a non-functional protein in humans [34] . Recently Schneider et al. [35] confirmed that the COX-3 protein is not detectable in human tissue and does not possess any catalytic activity in expression studies. Interestingly, Nurmi et al. [36] have observed an increase in the COX-3 transcript in human colonic tissue, but no protein was detected. This group has also shown that COX-3 is up-regulated in hypertonic conditions in a human colon cancer cell line, and transcript-specific degradation by RNA interference increases COX-1 and COX-2 mRNA, suggesting that, although the transcript is not translated, it may play a regulatory role in COXmediated osmoregulation. In humans, the COX-3 story is complicated even more by the fact that there are also two other spliced COX-1 forms that completely retain intron 1, but lack a nucleotide in one of two other positions, thus encoding full-length COX proteins. Qin et al. [37] have shown that at least one of these alternative forms catalyses the synthesis of PGF 2α from arachidonic acid, but no differential sensitivity to acetaminophen or NSAIDs was observed. This lack of sensitivity to acetaminophen was also confirmed by Censarek and co-workers [38] using site-directed mutagenesis to correct the frameshift. Therefore the relevance of COX-3 to human physiological and pathophysiological processes remains questionable at this time, and many reviews have focused on this dilemma [39] [40] [41] [42] [43] .
However, COX-3 has now been cloned in mouse and rat [44, 45] . In the mouse, the highest expression of COX-3 protein was observed in kidney, heart and neuronal tissues, as well as in the COX-1-knockout mouse [44] . The same expression pattern was observed in the rat; however, Snipes and co-workers [45] went on to show that, when expressed in COS-7 cells, COX-3 does not possess COX catalytic activity nor is it associated with PG inhibition by acetaminophen. In contrast, Davies et al. [41] have proposed that COX-3 is probably more important in the termination phase of the inflammatory response, hence the weak anti-inflammatory effect of acetaminophen. The identification of COX-3 is especially promising for PGI 2 biology, as suggested by Warner and Mitchell [46] , since acetaminophen has been shown to reduce circulating PGI 2 levels independent of actions on COX-2. As COX-3 is highly expressed in the rodent kidney, it will be interesting to see whether any novel renal processes may be associated with this third COX isoform.
The final step in the PG biosynthesis pathway is catalysed by specific terminal synthases/isomerases which determine which prostanoid will be formed. There is a great body of literature dealing with the functional coupling of terminal synthases with upstream COXs that is influenced by the availability of arachidonic acid and the subcellular localization of the enzymes. For instance, there are multiple forms of PGESs (PGE 2 synthases) that convert COX-derived PGH 2 into PGE 2 . In general, a membrane-associated PGES (mPGES-1) located in the perinuclear compartment of the cell preferentially couples to COX-2, whereas a cytosolic form of PGES (cPGES) predominantly couples with constitutive COX-1 [47] ; also mPGES-2 couples with both COX isoforms [48] . In a study by Campean et al. [49] , microsomal-type PGES expression was investigated along the rat and mouse nephron, showing parallel expression with COX-2 in the cortical thick ascending limb and macula densa, and co-expression with COX-1 in glomerular mesangial cells, distal convoluted tubule, connecting tubule and non-intercalated collecting duct cells, where COX-2 was absent. Cortical fibroblasts were positive for COX-1 and PGES in mice, and medullary interstitial cells expressed all three enzymes. In another study by Schneider et al. [50] , it was shown that mPGES-1 is highly expressed in rabbit distal convoluted tubule, medullary collecting ducts and cortical collecting ducts, predominantly co-localizing with COX-1 and, to a lesser extent, is co-expressed with COX-2 in macula densa and medullary interstitial cells. On the other hand, Murakami et al. [51] have shown that mPGES preferentially couples to COX-2 in a delayed PGE 2 biosynthesis response when arachidonic acid is limited. Coupling to COX-1 is enhanced if arachidonic acid supply is increased by activation of cPLA 2 . Thus, depending on the cell context or the cell type, renal PGE 2 synthesis may be mediated by either COX isoform.
In addition to PGES, which is the best characterized of the terminal synthases in the kidney, certain studies have determined the regional and cellular localization of other renal PG synthases. For example, Vitzthum et al. [52] have examined the mRNA expression of different PG synthases in microdissected rat nephron segments by RT-PCR (reverse transcriptase-PCR), indicating that (i) PGDS (PGD 2 synthase) is found in the proximal convoluted tubule, thick ascending limb, distal convoluted tubule, and cortical and outer medullary collecting duct; (ii) PGES is restricted to the entire collecting duct; (iii) TXAS (TXA 2 synthase) was found only in glomeruli; and (iv) PGIS (PGI 2 synthase) mRNA was present in the whole kidney, but not in any nephron segment examined. Although there are a number of studies highlighting the functional coupling between COX isoforms and these other synthases, these topics are beyond the scope of this review. Interestingly an extensive overview of these coupling profiles is provided by Ueno et al. [48] . Briefly, Ueno and co-workers have grouped the synthases into three categories: (i) the perinuclear enzymes that prefer COX-2 (PGIS, TXAS and mPGES-1); (ii) the cytosolic enzyme that prefers COX-1 (cPGES); and (iii) the translocating enzymes that utilize either COX in a stimulusdependent manner [H-PGDS (haemopoietic PGDS)]. Of interest to note, although there is a preference of each synthase for a COX isoform over the other, depending on many factors (stimulus, levels of cPLA 2 and immediate or delayed response), activation of the other COX pathway may be favoured. And of course, there are certainly many unidentified cofactors that may influence the coupling between each COX and prostanoid synthase in various cells. A schematic diagram summarizing the preferential association between these enzymes to determine PG biosynthesis is shown in Figure 1 .
Although our knowledge of the distribution of specific COX and terminal synthases in the kidney is expanding, there remains a great deal of controversy in the area. Despite these inconsistencies, the kidney is surely a major contributor of PG biosynthesis, and various groups have examined the relative amounts of each PG produced in specific areas along the nephron. A recent study by Qi et al. [28] has examined, by GC/MS, the profile of PGs produced in different regions of the mouse kidney, and have shown that PGE 2 is the major prostanoid in both the cortex and medulla, followed by PGI 2 , PGF 2α and TXA 2 ; however, PGD 2 was not detectable in either region. Although a plethora of renal functions have been proposed for the different PGs, the underlying mechanisms are not well-documented. At the glomerular level, they not only maintain renal blood flow and glomerular filtration rate, but also affect the secretion of renin. In addition, all along the tubules, they differentially regulate transport of H 2 O and solute in the specific segments of the nephron. In part, these diverse cellular effects of PGs are mediated by distinct G-protein-coupled receptors, each one having a greater affinity for a respective PG. There are two main classification schemes used to categorize the PG receptors. The general nomenclature is simple: the PGE 2 receptor is termed E-type PG receptor or EP, PGI 2 receptor is IP, TXA 2 receptor is TP and so on [5] . However, a phylogenetic classification of the receptors arranges them into three separate clusters based on their ability to relax or constrict vessels. Therefore cluster 1 receptors (EP 2 , EP 4 , IP and DP) are mainly vasodilatory receptors and stimulate adenylate cyclase, cluster 2 receptors (FP, TP and EP 1 ) have constrictor effects by increasing intracellular Ca 2+ , and cluster 3 receptors (EP 3 ) are inhibitory and decrease cAMP [3, 6, 10] . Table 1 summarizes each receptor, its main expression in renal cells, the signalling linked to receptor activation, as well as the major renal process associated with the pathway.
The remainder of this review will highlight the relevant findings since Y2K on each PG/PG receptor system in the kidney. The perinuclear enzymes are shown near the nucleus around the ER (endoplasmic reticulum), and the cytosolic enzymes are near the plasma membrane. As can be seen, cPLA 2 plays a key role for the release of bound arachidonic acid (AA), and this can be modulated by sPLA 2 . Perinuclear COX-2 or cytosolic COX-1 can then catalyse free arachidonic acid in their vicinity to an intermediate endoperoxide (PGH 2 ), which is then acted upon by specific synthases. In general, depending on the cell context, COX-2 endoperoxides will couple with PGES, PGIS, TXAS and PGDS to form PGE 2 , PGI 2 , TXA 2 or PGD 2 respectively. On the other hand, COX-1 preferentially associates with PGES, PGIS or TXAS to form PGE 2 , PGI 2 and TXA 2 respectively, as major products. At this time, there is no evidence that COX-1 contributes to renal PGD 2 synthesis, and the enzymes involved in renal PGF 2α biosynthesis have not been studied. ??, unknown. [60] . To date, there have been no major disturbances in tubular transport function associated with genetic manipulations of specific EP pathways. Accordingly, Kennedy et al. [61] recently described a process whereby PGE 2 acting on hypothalamic EP 1 (rather than collecting duct EP 1 ) regulates arginine vasopressin synthesis, contributing to a urine concentrating defect in mice lacking EP 1 .
Up until the new millennium, it was thought that PGs did not play a major role in the proximal tubule; however, a great deal of insight has been obtained since Y2K into the contribution of PGE 2 to proximal tubule transport function. For instance, in opossum kidney cells it has been shown that PGE 2 generated by the cell does not act as a counter ion, rather, via EP 4 , stimulates cAMP and activates PKA (protein kinase A) and, in turn, alters basolateral organic anion uptake [62] . This same response was also observed in rabbits and in a human proximal tubule cell line stably expressing OAT-1 (organic anion transporter-1) [63] . In contrast, Sauvant et al. [64] have recently described a process by which long-term exposure to PGE 2 inhibits its excretion by decreasing the levels of basolateral OAT-1 and OAT-3, which are responsible for PGE 2 uptake in rat renal proximal tubule cells. This is a proposed mechanism by which PGE 2 sustains its own levels in the blood, contributing to fever and inflammatory events. The underlying regulatory pathways are not completely understood, but short-term compared with long-term exposure to PGE 2 clearly has opposite effects on the overall cell response. In addition to these studies on basolateral OATs, the basolateral Na + -ATPase is also altered by PGE 2 in proximal tubules. Lopes and co-workers [65] have shown that Ang-(1-7)-induced Na + -ATPase activity is inhibited by bradykinin via PGE 2 . Also in a recent study, PGE 2 reduced phosphate transport in mouse proximal convoluted tubules [66] . Undoubtedly, the next decade will provide a great deal of advancement in clarifying the role of other prostanoids in the proximal tubule as well.
Another important role of PGE 2 in the kidney is the regulation of renin secretion. Jensen et al. [67] have shown that EP 4 was present in rat juxtaglomerular cells, consistent with the stimulatory effect of PGE 2 /cAMP on renin secretion. In a recent study by Chen et al. [68] , mice were generated using the Cre-loxP system under control of the renin promoter with nearly complete deletion of G s from juxtaglomerular granular cells. In these mice, the stimulatory response to PGE 2 was abolished, confirming the role of PGE 2 /cAMP in renin secretion. In another study, Friss et al. [69] used patch clamping to study the secretion of renin from juxtaglomerular cells isolated from rat cortex. In this study, both EP 2 and EP 4 were detected in the cells and were involved in PKA-mediated exocytosis and release of renin granules.
More recent studies have also revealed several interesting roles for PGE 2 in the kidney, beyond natriuresis/ diuresis or the regulation of renin release. For instance in a kidney distal tubule cell line, MDCK cells, PGE 2 derived from COX-2 has been shown to reduce epithelial-tomesenchymal transition by inhibiting TGF-β (transforming growth factor-β)-induced oxidant production and by mediating the HGF (hepatocyte growth factor)-induced antifibrotic response [70] . Furthermore, Aoudjit et al. [71] have demonstrated an anti-apoptotic and protective effect of COX-2-derived PGE 2 in glomerular epithelial cells mediated by EP 4 ; cultured glomerular epithelial cells as well as the acute puromycin aminonucleoside nephrosis rat model of glomerular epithelial cell injury and proteinuria were used in these studies. In addition, in stretched mouse podocytes, p38 MAPK activation leads to increases in COX-2 and EP 4 /cAMP production, which alters the actin cytoskeleton [72] . This may implicate the PGE 2 /EP 4 system in the disturbances in filtration barrier associated with many kidney diseases. As with EP 4 , EP 1 has also been detected in glomerular podocytes [73] and mesangial cells [74] , but their role in regulating glomerular filtration barrier function in various diseases is controversial. Rahal et al. [75] have recently observed a greater damage and impairment of renal function in nephritic mice lacking EP 1 , but no difference in the level of proteinuria. In contrast, EP 1 antagonism reduces proteinuria in diabetic [76] and spontaneously hypertensive [77] rats. The reason for this discrepancy has not yet been addressed, but may involve other as of yet unidentified processes linked to EP 1 signalling in the glomerular region.
In addition to a role in regulating filtration barrier function and glomerular permeability, PGE 2 acting on different EPs can influence vascular tone and renal haemodynamics. Therland et al. [78] have shown colocalization of EP 4 with COX-2 in the human kidney vasculature. Tang et al. [79] have also confirmed the expression of EP 4 in the rat afferent arteriole and, in this study, PGE 2 was shown to elicit its vasodilator effect via EP 4 /cAMP rather than EP 2 . Purdy and Arendshorst [80] also suggest that EP 4 is the main PGE 2 receptor in rat preglomerular microvessels, and this vasodilatory response through G s increases cAMP and reduces cytosolic Ca 2+ . However Imig et al. [81] have demonstrated a vasodilatory role for EP 2 in mouse afferent arterioles and confirmed in EP 2 -deficient mice that vasodilatory EP 2 responses buffer vasoconstrictor effects via EP 1 and EP 3 . In contrast, a study by Audoly et al. [82] has shown that baseline haemodynamics (renal blood flow and vascular resistance) were unchanged in mice lacking EP 2 , but mice lacking EP 3 had increased renal blood flow and decreased resistance. PGE 2 also vasoconstricts the rat afferent arteriole via EP 3 coupling with G i [79] . Taken together, PGE 2 acting on the four EP subtypes can cause vasodilatory or vasoconstrictor responses in the kidney and influence renal blood flow and haemodynamics, but the overall effect is dependent on many factors: relative expression of different EP subtypes; the presence of other hormonal signals, e.g. endothelin, AngII and NO; or the cell context (health compared with disease).
RENAL PGI 2 /IP SYSTEM
PGI 2 is a potent vasodilatory/relaxant prostanoid. As with PGE 2 , it is implicated in the regulation of renal haemodynamics, the release of renin and tubular transport responses. Its renal synthesis is dependent on either PGIS or PSF (PGI 2 -stimulating factor). Wu and Liou [83] have provided a recent review of PGIS structure and biology. Renal PGIS expression is lower than other tissues [84] , yet PGI 2 synthesis along the nephron is quite significant [27] [28] [29] [30] 85] . The highest regions are the glomeruli and inner medulla, especially the inner medullary collecting duct. On the other hand, PSF was detected in the glomerular vasculature regulating PGI 2 production by endothelial cells. At this time, it is not clear how PSF contributes to overall renal PGI 2 synthesis; however, PSF levels in the renal vasculature are diminished in streptozotocindiabetic rats, but the contribution to glomerular haemodynamic changes and the initial hyperfiltration seen in diabetes has not been established [86] .
The relevance of PGIS and PGI 2 in renal function is revealed in studies using kidney disease models or knockout mice. Tomida et al. [87] have shown that renal PGIS levels were altered in 5/6-nephrectomized rats. Levels were initially decreased in the cortical thick ascending limb, including the macula densa, at 1-2 weeks post-surgery, but increased in these same cells as well as mesangial cells in response to the reduction of renal mass at 8 weeks. A gross morphological assessment by Yokoyama et al. [88] showed atrophy, surface irregularities and cysts in PGIS-knockout mice. In addition, PGIS deficiency induced renal fibrosis and vascular injury, including arteriosclerosis and wall thickening in the kidney and aorta, consistent with the notable role of PGI 2 in maintaining vascular homoeostasis. Furthermore, fibrotic and necrotic lesions were distributed from the medulla to the cortex, along tubules and vessels, with increases in collagen IV. PGI 2 is known to have a protective effect in many cells. Consistent with this protective role of PGI 2 , in a recent study by Chen et al. [89] , overexpression of PGI 2 (adenovirus-mediated transfer of COX-1 and PGIS genes) prevented tubular cell apoptosis in adriamycintreated rats by inhibiting NF-κB (nuclear factor κB).
Our group has recently published a comprehensive review on PGI 2 and its signalling options in the kidney [8] , highlighting the relevance to renal function in health and disease. A few other reviews on PGI 2 and IP have been published since Y2K [90] [91] [92] [93] . Another recent review by Ruan and Dogne [94] focuses on the potential therapeutic strategies for targeting PGI 2 function and its implications for cardiovascular and other PGI 2 -related diseases. An example of such a strategy was undertaken by the same group [95] , whereby they engineered a fusion protein by linking COX-2 and PGIS. This fusion enzyme was expressed in HEK-293 and COS-7 cells and displayed three catalytic functions (arachidonic acid conversion into PGG 2 , PGH 2 and PGI 2 ) to increase PGI 2 biosynthesis and inhibit platelet aggregation induced by arachidonic acid, and thus could be used as a potential intervention for treatment of TXA 2 -mediated cardiovascular disorders.
Many of the renal effects of PGI 2 are mediated by the cell-surface IP [8] , and the main signalling pathway linked to activation of IP in renal cells is stimulation of cAMP. However, increases in intracellular Ca 2+ and inhibition of adenylate cyclase have also been observed in renal cells. Studies since the start of the millennium have revealed many regulatory mechanisms that are implicated in the promiscuous coupling of IP to different downstream signalling pathways, including post-translational modification of the receptor, such as isoprenylation [97] , farnesylation [98] , phosphorylation [99] [100] [101] [102] and glycosylation [103] . Another interesting feature of human IP is that it can form dimers/oligomers [91] in an agonistindependent fashion [104] . In a study by Wilson et al. [105] , dimerization between IP and TP has been demonstrated in HEK-293 cells, favouring cAMP generation linked to TP activation. The authors went on to suggest that this provides a mechanism by which IP can limit TP-mediated effects. In a recent study [106] , it was also shown that this dimerization permitted the regulation of receptor endocytosis in vascular smooth muscle cells, determined by activation of the dimeric partner. These different regulatory events that determine IP-mediated effects diversify the role of the PGI 2 /IP system in the kidney and highlight its significance to kidney function.
There seems to be some controversy across most species with respect to IP localization in specific renal cells. For instance, high levels of IP mRNA are present in Tamm-Horsfall-positive tubules (mTAL) of the rat outer medulla [55] , but human studies indicate that both IP protein and mRNA are only found in non-mTAL tubules of the outer medulla [107] . In addition, IP is present in human mesangial cells and podocytes [107] , but only in rodent mesangial cells and not podocytes [73, 96, 108] . In comparison, our group has described rat IP expression [55, 96, 109, 110] , and IP was detected in glomeruli (mesangial cells), interstitial cells, the vasculature and the tubular epithelial cells (proximal tubule, mTAL and collecting duct). Our laboratory was the first to confirm IP expression in proximal tubule cells, but the relevance to function of this nephron segment in health and disease has not yet been explored. A study by Yamashita et al. [111] has reported the expression of IP protein in rat afferent arterioles and glomeruli, but no reference was made to localization in other parts of the rat nephron. Overall, the expression pattern of IP is consistent with the documented role of PGI 2 in the kidney, regulating renal and glomerular haemodynamics, renin secretion, as well as tubular transport processes. Interestingly, we have also reported a reduction in IP levels in streptozotocindiabetic rats [109] , and a general attenuation of the PGI 2 / IP system in cultured mesangial cells exposed to high glucose. In these studies, PGI 2 analogues altered matrix proteins and matrix metalloproteinases, suggesting that targeting IP could be a therapeutic approach to reduce matrix changes associated with diabetic nephropathy or other kidney diseases.
Murata et al. [112] have produced a recombinant mouse lacking IP, but these mice were normotensive and displayed no obvious renal pathology. Upon further characterization, Yahata et al. [113] reported that IPknockout mice exhibit salt-sensitive hypertension and enhanced renin release following water deprivation; however, in a study by Fugino et al. [114] , the PGI 2 /IP system was shown to be an important regulator of renovascular hypertension and a critical mediator of renin release. In IP-knockout mice, blood pressure, plasma renin activity and renal renin mRNA were lower than wild-type littermates in response to renal artery stenosis. Despite the abundance of IP in the kidney, the mild renal phenotype in the IP-knockout compared with PGIS-deficient mice [88] suggests that PGI 2 interactions in the kidney are a great deal more elaborate, and PGI 2 acting on IP-independent pathways, such as activation of PPARδ (peroxisomeproliferator-activated receptor δ) or other signalling systems, may play a more dominant role in renal PGI 2 biology. Although it has been shown that PGI 2 regulates gene expression by activating the PPARδ pathway [115, 116] , very little was known about its role in the renal system. Hatae et al. [117] have studied the PGI 2 /PPARδ effects on cell apoptosis, demonstrating that the PGI 2 /IP/cAMP pathway antagonizes the effects mediated by the PPARδ pathway in HEK-293 cells. In studies by Hao et al. [118, 119] , it has been demonstrated that COX-2-derived PGI 2 activates downstream PPARδ to protect cultured medullary interstitial cells from hypertonicityinduced cell death. Similarly, Ishaque et al. [120] have reported that PGI 2 derived from COX-2 plays an important anti-apoptotic role against TNF-α-mediated apoptosis of glomerular mesangial cells characteristic of rat glomerular nephritis. Therefore the pro-or anti-apoptotic nature of the PGI 2 system is highly dependent on the cell context, as well as the specific contribution of IP and/or PPARδ pathways in a given cell. Taken together, it appears that the PGI 2 /PPARδ system may be more important for renal disease processes, especially since PGI 2 is a major product of COX-2, and both COX-2 and PGIS deficiencies in mice lead to severe nephropathy, yet targeted deletion of IP has little effect on the healthy renal system.
THE RENAL TXA 2 /TP SYSTEM
In contrast with PGI 2 , TXA 2 is a potent vasoconstrictor and signals via TP to increase intracellular Ca 2+ . There are two known TP isoforms: TP α and TP β . TPs have been localized to the renal vasculature, glomerular mesangial cells and podocytes and various nephron segments [73, [121] [122] [123] [124] [125] . Interestingly, both isoforms are regulated by PKC-induced phosphorylation and desensitization in response to EP 1 and FP activation [126] , and TP α undergoes desensitization in response to PGD 2 [127] as well as PGI 2 [128] . In addition to intracellular Ca 2+ signalling, TXA 2 acting on TP can activate other pathways. For example, both TP isoforms can activate ERK in HEK-293 cells, but this involves PKC-, PKA-and PI3K (phosphoinositide 3-kinase)-dependent mechanisms [129] . Furthermore, in HEK-293 cells, activation of TP α induces GSK-3 (glycogen-synthase kinase-3) phosphorylation via PKA and PI3K which, in turn, activates β-catenin/Tcell factor pathway and stimulates cell proliferation and cellular transformation [130] .
In addition to TXA 2 , the PG endoperoxide PGH 2 [131] as well as isoprostanes [132] , non-enzymatic oxidation products of arachidonic acid, can activate TPs. Since the start of the millennium, there are several studies that are revealing a role for TP independent of TXA 2 , but dependent on TP activation by isoprostanes. For instance, in spontaneously hypertensive rats, TP plays a role in the gender difference in blood pressure that is observed, but TXA 2 itself is not involved [133] . In addition, Welch [134] has described a role for 8-isoPGF 2α in enhancing tubuloglomerular feedback via activation of TP, which is independent of salt due to stimulation of NO. Furthermore, in a recent study, Sasaki et al. [135] have described the dimerization between TP α and TP β that could influence TP-mediated responses. Wilson and coworkers [136] have shown recently that this dimerization enhances isoprostane-mediated increases in inositol phosphate and intracellular Ca 2+ in HEK-293 cells. A key role for TXA 2 is in the regulation of renal haemodynamics and, since Y2K, various studies have characterized this role. In a study by Cavarape et al. [137] , the constrictor effect of TXA 2 on the arcuate artery (renal conduit vessel) was shown to be mediated by activation of the Rho-kinase pathway. Also, Kawada et al. [138] have shown that TP-knockout mice have reduced renal blood flow, but increased filtration fraction and renal vascular resistance. Furthermore, the TXA 2 /TP system has been shown to cross-talk with the renin-Ang system. For instance, activation of TP in response to AngII acting on AT 1 (AngII type 1) receptors results in increased generation of ROS (reactive oxygen species) and TXB 2 , but decreases in NO. An important role for the TXA 2 /TP system in the kidney is that it mediates the effects of AngII on renal vascular resistance. Wilcox and Welch [139] have demonstrated that high salt increased TP expression in the rat cortex, but AngII reduced TP expression. On the other hand, inhibition of the AT 1 receptor with losartan reversed the salt effect such that, in low salt, TP expression was increased. AngII had no effect on TXAS, which was increased by high salt in the kidney cortex. The acute pressor response to endothelin in Sprague-Dawley rats is also dependent on TP activation [140] , as well as the slow pressor response to AngII [141] . Additionally, TXA 2 /TP partially mediates the constrictor effect of AngII on rat outer medullary descending vasa recta [142] .
Another important role for the TXA 2 /TP system in the kidney is the regulation of mesangial cell function, including growth responses [142] and matrix synthesis [143] . For example, TXA 2 has been shown to act as a co-mitogen for PDGF (platelet-derived growth factor)-stimulated growth of mesangial cells [144] . In contrast, TP activation in rat mesangial cells reduces ANP (atrial natriuretic peptide)-mediated inhibition of thymidine incorporation [145] . In addition, Coffman et al. [146] have shown that TP activation by TXA 2 increases the production of PAI-1 (plasminogen activator inhibitor-1) and plasminogen activators by mesangial cells, which could modulate glomerular thrombosis and fibrosis in inflammatory diseases. Consistent with this role, Okumura and co-workers [147] have reported a reduction in intraglomerular thrombi and glomerulosclerosis in response to inhibition of TXAS in diabetic rats.
The TXA 2 /TP system has been implicated in the glomerular changes associated with various kidney diseases. For example, in nephritic mice, TP activation increased the uptake and reduced the disposal of heataggregated BSA by mesangial cells [148] . In addition, in a recent study by Xu et al. [149] , TP antagonism was studied in streptozotocin-diabetic ApoE (apolipoprotein E)-knockout mice, resulting in attenuation of various markers of oxidative stress and inflammation, as well as decreasing albuminuria and diabetic nephropathy. Consistent with this role in diabetes, in streptozotocindiabetic rats the ratio of PGI 2 /TXA 2 is diminished, but vitamin E treatment restores kidney function and rectifies the balance between PGI 2 and TXA 2 that is disturbed in diabetes [150] . In addition, in the Otsuka Long-Evans Tokushima Fatty rat (a model of Type 2 diabetes), a TXAS inhibitor was beneficial in reducing glomerular change and proteinuria [147] . TP activation is also implicated in the renal vasoconstriction in Escherichia coli LPS (lipopolysaccharide)-endotoxaemic mice [151] . Another important finding since Y2K is that TP activation can regulate cellular invasion responses to trefoil peptides and src, which are implicated in inflammation and cancer progression. This TP-dependent invasion pathway involves the PKC signalling cascade and not Rho-or G α12 /G α13 -dependent mechanisms [152] . Taken together, these studies support the idea that antagonizing the TXA 2 /TP system could be beneficial for many renal diseases.
THE RENAL PGD 2 /DP SYSTEM
PGD 2 signals through DP to increase cAMP. To this day, the role of PGD 2 and its receptor in the kidney remain poorly defined. Although DP localization in the kidney has not been determined in any species [153, 154] , indirect evidence does suggest its presence. For example Rao et al. [155] infused PGD 2 into the kidney and showed haemodynamic effects (increased renal blood flow, urine output and creatinine clearance) as well as altered tubular transport (Na + and K + excretion), but there is the possibility that other receptors are involved in these effects. Interestingly, in a study by Fernandez-Tome et al. [156] , it is was shown that PGD 2 derived from COX-2 in the renal papilla plays a key role in the maintenance of phosphatidylcholine biosynthesis, which is needed for cell integrity, and inhibition of PGD 2 may underlie the papillary necrosis associated with NSAIDs. A role for PGD 2 in preventing renal fibrosis has also been suggested. In a recent study by Zhang et al. [157] , the antifibrotic (maintenance of epithelial-like morphology, E-cadherin levels and α-smooth muscle actin) action of PGD 2 was attributed to an antioxidant effect, independent of DP 1 or DP 2 , in distal tubule epithelial kidney cells (MDCK cells) treated with TGF-β to induce epithelial-to-mesenchymal transition.
Although there remain only a handful of reports that directly examine the effects of renal PGD 2 , other studies describe the role of its stable metabolite 15d-PGJ 2 (15-deoxy-D 12,14 -PGJ 2 ) as well as its interaction with the PPARγ transcription factor. Kang et al. [158] have shown that 15d-PGJ2 promotes apoptotic cell death in opossum kidney proximal tubule cells via ROS production and inhibition of NF-κB. In addition, 15d-PGJ2 stimulated ERK activity and proliferation of opossum kidney cells [159] , and this effect was inhibited by PPARγ antagonism. In mesangial cells, 15d-PGJ 2 has PPAR-independent effects, for instance inducing the re-organization of cytoskeletal proteins, such as vimentin and tubulin, and targeting proteins involved in oxidative stress, including Hsp (heat-shock protein) 90 [160] , and also covalent modification of cellular thiols [161] . Furthermore, in mouse inner medullary collecting duct cells (IMCD3), Neuhofer et al. [162] have shown that 15d-PGJ 2 regulates tonicity induced expression of Hsp70 and susceptibility to high urea concentrations. A clearer perspective on PGD 2 /DP involvement in specific renal processes will be obtained when DP expression in the kidney has been determined, and renal studies with highly selective DP antagonists or DP-knockout models are performed.
THE RENAL PGF 2α /FP SYSTEM
PGF 2α acts on two FP isoforms, FP A and FP B , that are generated by alternative mRNA splicing in their Cterminus. Agonist stimulation of the spliced variants results in activation of G q and Rho signalling pathways [163] , and FP B can activate transcription through a β-catenin pathway [164] . For instance, Fujino and Regan [165] have expressed FP B in HEK-293 cells and observed an increase in COX-2 promoter activity that is Rho/β-catenin-dependent and PKC-independent. This group also showed that PGE 2 attenuated β-catenin signalling in response to PGF 2α but had no effect on inositol phosphate stimulation [166] . FP has been cloned from several species, including mouse, rat, pig, rabbit and human [167] [168] [169] [170] . The intrarenal localization of FP mRNA was first described by Saito et al. [171] in mice, showing expression in the distal convoluted tubule and principal cells of the collecting duct, but not in glomeruli, proximal tubules or thick ascending limbs. Bek et al. [73] detected FP in mouse podocytes linked to increases in intracellular Ca 2+ in response to PGF 2α . The distribution of renal FP was recently examined by Hébert et al. [169] in rabbit kidney, showing a higher expression in more distal parts of the nephron, especially the cortical collecting duct.
A functional role for PGF 2α /FP was also revealed by Hébert and co-workers [169] , whereby FP activation by latanoprost (a selective agonist) inhibited arginine vasopressin-stimulated water transport in in vitro microperfused rabbit cortical collecting duct. Interestingly, activation of FP did not alter intracellular Ca 2+ in these cells. Of importance, the effect of latanoprost was additive to that of sulprostone (an EP 3 agonist), confirming further the involvement of FP in these studies. Therefore, in the cortical collecting duct, FP couples with a pertussistoxin-sensitive pathway to regulate water transport, rather than the usual G q -mediated responses. Moreover, in rat kidney fibroblasts, PGF 2α acting on FP causes cell transformation by increasing intracellular Ca 2+ and activating Ca 2+ -dependent Cl − channels [172] ; future studies should determine whether the PGF 2α /FP system contributes to cell transformation in kidney diseases. Considering that a substantial amount of PGF 2α is produced in the kidney, the next decade will surely reveal a greater diversity of renal processes associated with activation of the PGF 2α /FP system.
CONCLUDING REMARKS
There have been many developments since Y2K to further our understanding of how PGs regulate renal function, particularly with respect to differences in PG synthesis associated with each COX isoform and the contribution of individual PG pathways to important renal processes, such as the secretion of renin. There is also the complexity of the system in terms of cross-talk between the different PG biosynthesis enzymes, as well as between different PG receptor pathways. Despite these advances, there remains a great deal of controversy in the literature, especially concerning the use of COX-2-selective inhibitors and the renal complications that may arise. A greater intricacy of PG involvement in renal health and disease may also be expected, due to many new avenues for research, such as the contribution of COX-3 or PPARs. There also remain many other unanswered questions and alternatives to the 'classical' COX/PG field, but considering the diversity in molecular biology tools (e.g. Cre-loxP recombination, mouse knockouts etc.) and the pharmacological agents that selectively target one component of the system (synthesis enzymes, receptors etc.), the future should provide many new insights to address these uncertainties. The future also proves to be promising with respect to novel therapeutic strategies for preventing or manipulating the outcome of kidney diseases, especially diabetic nephropathy.
